WHO gives emergency use listing to Moderna’s COVID-19 vaccine

0

GINOWAN, JAPAN - APRIL 28: Moderna vaccines are prepared for application at a United States military vaccination centre at Camp Foster on April 28, 2021 in Ginowan, Japan. A United States military vaccination program aiming to inoculate all service personnel and their families against Covid-19 coronavirus is under way on Japans southernmost island of Okinawa, home to around 30,000 US troops and one of the largest US Marine contingents outside of mainland USA. (Photo by Carl Court/Getty Images)©

GINOWAN, JAPAN – APRIL 28: Moderna vaccines are prepared for application at a United States military vaccination centre at Camp Foster on April 28, 2021 in Ginowan, Japan. A United States military vaccination program aiming to…ZURICH, April 30 (Reuters) – The World Health Organization has listed Moderna’s COVID-19 vaccine for emergency use, the agency said on Friday, the fifth to be given the status meant to expedite countries’ own approval of shots.

“The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency,” the WHO said in a statement.

WHO Assistant Director-General Mariangela Simao said on Friday it was important to have more vaccines available because of supply problems for other shots, including from India, a main source of vaccines for the global COVAX vaccine sharing program. India has restricted exports because of a crisis of infections.

Moderna announced this week an expansion plan for its production network to boost its capacity to up to 3 billion doses in 2022.

The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) already in January had recommended Moderna’s vaccine for all age groups 18 and above.

Pfizer and its German partner BionTech’s shot, also an mRNA vaccine like Moderna’s, was the first vaccine to get a WHO emergency use listing in the final hours of 2020.

Since then, the WHO has added vaccines from Astrazeneca-SK Bio, Serum Institute of India and Johnson & Johnson vaccines to the list.

The Geneva-based health organization is still considering COVID-19 vaccines from Sinopharm and Sinovac following an extended review, with decisions due by the end of next week.

FIRST BANK ADVERT
Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More